Anti-human EGFR IgG1 monoclonal antibody was applied to 64Cu-DOTA-MS2 VLP to actively target EGFR-overexpressing HCC1954 breast cancer (Aanei et al., 2016); p-aminophenylalanine (paF) unnatural amino acid was introduced at position 19 of the MS2 capsid proteins, followed by reacting with aminophenol-antibody conjugates. Here, EGFR is linked to breast carcinoma.